IP Library Granted Patent US 7,410,648
Granted Patent B2
US 7,410,648 · App. 10/495,643 · Granted Aug 12, 2008

Polypeptides of

Assignee: ID Biomedical Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,410,648
App. No.
10/495,643
Granted
Aug 12, 2008
Kind
B2
Abstract

The present invention relates to polypeptides, more particularly polypeptides of Moraxella ( Branhamella ) catarrhalis which may be used to prevent, diagnose and/or treat Moraxella ( Branhamella ) catarrhalis infection.

Claims (11)

1. An isolated polypeptide consisting of an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO:2, wherein the polypeptide is capable of eliciting an antibody that specifically bonds to a protein consisting of the amino acid sequence set forth as SEQ ID NO:2, and wherein the polypeptide is capable of eliciting an immune response against Moraxella catarrhalis.

2. The isolated polypeptide according to claim 1 consisting of an amino acid sequence at least 95% identical to the amino sequence set forth as SEQ ID NO:2.

3. The polypeptide according to claim 1 consisting of an amino acid sequence at least 99% identical to the amino acid sequence set forth as SEQ ID NO:2.

4. The polypeptide according to claim 1 wherein the polypeptide consists of an amino sequence identical to the sequence set forth as SEQ ID NO:2.

5. An isolated polypeptide consisting of an amino acid sequence at least 95% identical to the amino acid sequence set forth as SEQ ID NO:2 from which the signal peptide consisting of the amino acid sequence set forth as SEQ ID NO:13 id deleted, where the polypeptide is capable of eliciting an antibody that specifically binds to a protein consisting of the amino acid sequence set forth as SEQ ID NO:2, and wherein the polypeptide is capable of an immune response against Moraxella catarrhalis.

6. The polypeptide according to claim 5 consisting of an amino acid sequence at least 99% identical to the amino acid sequence set forth as SEQ ID NO:2 from which the signal peptide sequence is deleted.

7. The polypeptide according to claim 5 consisting of the amino acid sequence set forth as SEQ ID NO:2 from which the signal peptide sequence is deleted.

8. An isolated polypeptide consisting of the amino acid sequence set forth as SEQ ID NO:2 from which the N-terminal valine residue is deleted, wherein the polypeptide is capable of eliciting an antibody that specifically binds to a protein consisting of the amino acid sequence ser forth as SEQ ID NO:2, and wherein the polypeptide is capable of eliciting an immune response against Moraxella catarrhalis.

9. A pharmaceutical composition comprising a polypeptide according to any one of claims 1 , 2 , and 3 - 8 and a pharmaceutically acceptable carrier, diluent or adjuvant.

10. A pharmaceutical composition comprising a polypeptide according to any one of claims 1 , 2 , and 3 - 8 and a liposome.

11. A kit comprising a polypeptide according to either claim 4 or claim 7 for detection or diagnosis of Moraxella catarrhalis infection.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2006
From: SHIRE BIOCHEM INC.
To: ID BIOMEDICAL CORPORATION
Reel/Frame 018131/0564 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2004
From: MARTIN, DENIS; JAMEL, JOSEE; BRODEUR, BERNARD R.; RIOUX, STEPHANE; COUTURE, JULIE
To: SHIRE BIOCHEM INC.
Reel/Frame 016192/0712 →
Continuity (2)
Provisional Application 6033144100 · Nov 16, 2001
Related Publication 20050070691A1 · Mar 31, 2005